{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:58Z","timestamp":1777420858457,"version":"3.51.4"},"reference-count":26,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T00:00:00Z","timestamp":1577318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:p>Background: BK virus hemorrhagic cystitis (BKV-HC) is a common complication following hematopoietic stem cell transplant (HSCT); optimal management remains uncertain. Supportive care (bladder irrigation and blood transfusions) and intravenous and intravesicular cidofovir have all been used with varying success. Objective: The purpose of this study was to determine the safety and effectiveness of intravesicular cidofovir for BKV-HC following HSCT. Methods: A retrospective analysis of all HSCT patients with BKV-HC prescribed intravesicular cidofovir from 2012 to 2017. Results: 33 patients were treated for BKV-HC. The median age was 50 years (range 23-73), and 18 (55%) were male. The median HC symptom severity was 2, with a median BK urine viral load pretreatment of 100,000,000 IU\/mL. Patients received a median of 2 intravesicular treatments (range 1-7) at a dosage of 5 mg\/kg per instillation. In all, 19 (59%) patients demonstrated complete clinical resolution of symptoms; 9 (28%) had a partial response; and 4 (13%) had no change in symptoms. Patients with a high pretreatment BK viral load (&gt;100 million) and high HC grade (2-4) had a lower frequency of complete remission. The main side effect of intravesicular instillation was severe bladder spasms in 4 patients (12%). Conclusion and Relevance: This is the largest study of intravesicular cidofovir treatment of BKV HC reported to date; 88% of patients with BVK-HC achieved clinical improvement of symptoms with minimal side effects. Clinical trials of intravesicular cidofovir could provide further evidence for this treatment for BKV-HC.<\/jats:p>","DOI":"10.1177\/1060028019897896","type":"journal-article","created":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T08:36:47Z","timestamp":1577349407000},"page":"547-553","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["Intravesicular Cidofovir in the Treatment of BK Virus\u2013Associated Hemorrhagic Cystitis Following Hematopoietic Stem Cell Transplantation"],"prefix":"10.1177","volume":"54","author":[{"given":"Graham M.","family":"Tooker","sequence":"first","affiliation":[{"name":"University of Maryland Medical Center Midtown Campus, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen A.","family":"Stafford","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Nishioka","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashraf Z.","family":"Badros","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7399-6406","authenticated-orcid":false,"given":"David J.","family":"Riedel","sequence":"additional","affiliation":[{"name":"University of Maryland School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,12,26]]},"reference":[{"key":"bibr1-1060028019897896","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.235"},{"key":"bibr2-1060028019897896","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1971"},{"key":"bibr3-1060028019897896","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13635"},{"key":"bibr4-1060028019897896","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.11.5394-5396.2004"},{"key":"bibr5-1060028019897896","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198607243150405"},{"key":"bibr6-1060028019897896","doi-asserted-by":"publisher","DOI":"10.1086\/344060"},{"key":"bibr7-1060028019897896","doi-asserted-by":"publisher","DOI":"10.1016\/J.MICINF.2012.02.002"},{"key":"bibr8-1060028019897896","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx324"},{"key":"bibr9-1060028019897896","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(03)00770-9"},{"key":"bibr10-1060028019897896","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702487"},{"key":"bibr11-1060028019897896","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705678"},{"key":"bibr12-1060028019897896","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.247"},{"key":"bibr13-1060028019897896","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3062.2001.003001044.x"},{"key":"bibr14-1060028019897896","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2008.02269.x"},{"key":"bibr15-1060028019897896","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.12.009"},{"key":"bibr16-1060028019897896","first-page":"738","volume":"24","author":"Cundy KC","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"bibr17-1060028019897896","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20567"},{"key":"bibr18-1060028019897896","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.04.009"},{"key":"bibr19-1060028019897896","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-017-0044-x"},{"key":"bibr20-1060028019897896","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.12.490"},{"key":"bibr21-1060028019897896","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2935-8"},{"key":"bibr22-1060028019897896","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.5.1103"},{"key":"bibr23-1060028019897896","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE): Version 5.0. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf. Published November 27, 2017. Accessed November 15, 2019."},{"key":"bibr24-1060028019897896","doi-asserted-by":"publisher","DOI":"10.1016\/J.JIAC.2016.01.013"},{"key":"bibr25-1060028019897896","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv393"},{"key":"bibr26-1060028019897896","doi-asserted-by":"publisher","DOI":"10.1053\/J.AJKD.2012.09.020"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028019897896","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028019897896","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028019897896","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:23Z","timestamp":1777374923000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028019897896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,26]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1177\/1060028019897896"],"URL":"https:\/\/doi.org\/10.1177\/1060028019897896","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,26]]}}}